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Introduction
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www.cdc.gov/vaccines/hcp/acip-recs/general-
recs/index.html
General Best 
Practice 
Guidelines 
General 
Recommendations=
–Timing and spacing
–Contraindications and precautions
–Preventing and managing adverse reactions to immunization
–Vaccine administration
–Storage and handling
–Altered immunocompetence
–Special situations
–Vaccination records
–Vaccination programs
–Vaccine information sources
General Best Practice Guidelines for Immunization
General “Recommendations” on Immunization
 Pink Book chapter
• Timing and spacing
• Contraindications and precautions
Timing 
and 
Spacing
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Interval between receipt of antibody-
containing blood products and live vaccines
Interval between doses of different vaccines 
not administered simultaneously
Interval between subsequent doses of the 
same vaccine
Timing and Spacing Issues
Antibody-containing 
Blood Products
 Used to restore a needed component of blood or provide a 
passive immune response following disease exposure.
 Sometimes circumstance dictates the use of antibody-
containing blood products along with a vaccine.
Antibody and Live Vaccines
 Inactivated vaccines are generally not affected by circulating 
antibody to the antigen
 Live, attenuated vaccines might be affected by circulating 
antibody to the antigen – an effectiveness concern
General Rule
Antibody Products and 
Measles- and Varicella-containing Vaccines
Product given first
Vaccine
Antibody
Action
Wait 2 weeks 
before giving antibody
Wait at least 3 months before giving 
vaccine
Appendix A24: Interval Between Antibody-Containing 
Products and Measles- and Varicella-Containing 
Vaccines
https://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/a/mmr_ig.pdf
Spacing of Antibody-containing Products and MMR and 
Varicella Vaccines
Product
Hepatitis A (IG)
Washed red blood cells
Measles prophylaxis (IG)
(immunocompetent recipient)
Plasma/platelet products
Intravenous immune globulin (IGIV)
0 months
3 months
6 months
7 months
7-11 months
Interval
Antibody-vaccine spacing recommendations apply 
specifically to MMR and varicella-containing vaccines
Do NOT apply to: 
–Zoster vaccine (large amount of virus in the vaccine) 
–Yellow fever, oral typhoid vaccines (negligible 
antibody in the U.S. blood supply)
–LAIV (viruses change annually)
–Rotavirus (replication in GI tract)
Exceptions to the General Rule
Palivizumab (Synagis)
 Contains only monoclonal RSV antibody
 Does not interfere with live virus vaccination
Red blood cells (RBCs), washed
 Negligible antibody content
Products Containing Type-specific 
or Negligible Antibody
Interval Between Doses of Different Vaccines
 Simultaneous administration
 Non-simultaneous administration
Simultaneous Administration
General Rule
 All vaccines can be administered at the same visit as all 
other vaccines.
 Exceptions: 
• PCV13 and PPSV23: Give PCV13 first
• MCV4-D (Menactra only) and PCV13 in asplenic or HIV infected 
persons:  Give PCV13 first
Combination
2 live injected OR 
1 live injected and 1 intranasal 
influenza vaccine
All other vaccines
One exception
Menactra and DTaP
Minimum interval
4 weeks
None
6 months
Non-simultaneous Administration:
Live-vaccine Effectiveness
Spacing of Live Vaccines Not 
Given Simultaneously
 If 2 live parenteral or intranasal vaccines are given less than 
28 days apart, the vaccine given second should be repeated.
 Antibody response from first vaccine interferes with 
replication of second vaccine.
Intervals Between Doses
General Rule
• Increasing the interval between doses of a multidose vaccine 
does not diminish the effectiveness of the vaccine.
Extended Interval Between Doses
 Not all variations among all schedules for all vaccines have 
been studied
 Available studies of extended intervals have shown no 
significant difference in final titer
 It is not necessary to restart the series or add doses because 
of an extended interval between doses
Intervals Between Doses
General Rule
 Increasing the interval between doses of a multidose vaccine 
does not diminish the effectiveness of the vaccine.
 Decreasing the interval between doses of a multidose vaccine 
may interfere with antibody response and protection.
https://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/a/age-interval-table.pdf
Included in Pink Book Appendix A-13
Minimum Intervals and Ages
 Vaccine doses should not be administered at intervals 
less than the minimum intervals or earlier than the 
minimum age.
When Can Minimum Intervals Be Used?
 Catch-up for a lapsed vaccination schedule 
 Impending international travel
 NOT to be used routinely
The “Grace Period”
 ACIP recommends that vaccine doses given 
up to four days before the minimum interval 
or age be counted as valid
 Should not be used for scheduling future 
vaccination visits
 Use for reviewing vaccination records
Use of the “Grace Period”
To schedule a future 
appointment
When evaluating a 
vaccination record
Client is in the office or 
clinic early
NO!
Yes
Maybe
Client is in the office or clinic
Use of the “Grace Period”
• Client/parent is 
known and 
dependable
• Client/parent is 
unknown or 
undependable
Reschedule
Vaccinate
Use of the “Grace Period”
 Basic principles
• The recommended interval or age is 
preferred
• The minimum interval can be used to catch 
up
• The grace period is last resort
Violations of 
Minimum Intervals and Minimum Ages
 Grace period may conflict with some state school entry 
requirements
 Immunization programs and/or school entry requirements 
may not accept some or all doses given earlier than the 
minimum age or interval, particularly varicella and/or MMR 
vaccines
 Providers should comply with local and/or state 
immunization requirements
Violations of 
Minimum Intervals and Minimum Ages
Minimum interval/age has been violated
Dose invalid
The repeat dose should be administered at 
least a minimum interval from the invalid 
dose
Contraindications 
& 
Precautions
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Vaccine Adverse Reaction
Adverse reaction
• Extraneous effect caused by vaccine
•“Side effect"
Vaccine Adverse Reaction
Adverse reaction
Adverse event
•Any medical event following vaccination
• May be true adverse reaction
• May be only coincidental
Vaccine Adverse Reactions
 Local
•Pain, swelling, redness at site of injection
•Common with inactivated vaccines
•Usually mild and self-limited
Vaccine Adverse Reactions
 Local
Systemic
•Fever, malaise, headache
• Nonspecific
• May be unrelated to vaccine
Live, Attenuated Vaccines
 Must replicate to produce immunity
 Symptoms usually mild
 Occur after an incubation period
(usually 3-21 days)
Vaccine Adverse Reactions
 Local
Systemic
Allergic
•Due to vaccine or vaccine component
• Rare
• Risk minimized by screening
Contraindication
A condition in a recipient that greatly
increases the chance of a serious adverse 
event
Precaution
A condition in a recipient that may increase 
the chance or severity of an adverse event
May compromise the ability of the vaccine to 
produce immunity 
Might cause diagnostic confusion
Permanent Contraindications
Severe allergic reaction to a prior dose of 
vaccine or to a vaccine component 
Permanent Contraindications
Rotavirus vaccines only
•Severe Combined Immunodeficiency disease 
(SCID) 
•History of intussusception
Pertussis vaccines only
• Encephalopathy not due to another 
identifiable cause occurring within 7 days 
of pertussis vaccination
Contraindications and Precautions
Condition
Allergy to component
Encephalopathy
Pregnancy
Immunosuppression
Moderate/severe illness
Recent blood product
Live
C
---
C
C
P
P**
Inactivated
C
C
V*
V
P
V
C=contraindication   
P=precaution  
V=vaccinate if indicated
*Except HPV
**MMR and varicella-containing (except zoster vaccine and LAIV)
Included in Pink Book Appendix A-28-30
https://www.cdc.gov/vaccines/hcp/acip-recs/general-
recs/contraindications.html
Vaccination During Pregnancy
 Live vaccines should not be administered to 
women known to be pregnant.
 In general, inactivated vaccines may be 
administered to pregnant women for whom 
they are indicated.
HPV vaccine should be deferred during 
pregnancy. 
 Inactivated vaccines – influenza and Tdap
 Other vaccines
 In general, inactivated vaccines can be administered
– NO CONTRAINDICATIONS
– Precautions (risk-benefit decision) – MenB, IPV
– Special considerations: https://www.cdc.gov/vaccines/schedules/hcp/imz/adult-
conditions.html and https://www.cdc.gov/vaccines/schedules/hcp/imz/child-
indications.html
• RZV, HPV-delay
• Hib, PCV13-no recommendations language at all
• HepA, HepB, MenACWY, PPSV23 – give if another risk factor is present 
Vaccination during Pregnancy
Vaccination of 
Immunosuppressed Persons
 Live vaccines should not be administered to 
severely immunosuppressed persons.
Persons with isolated B-cell deficiency (i.e. 
deficiency in humoral immunity) may receive 
varicella and zoster vaccine.
 Inactivated vaccines are safe to use in 
immunosuppressed persons, but the 
response to the vaccine may be decreased.
Immunosuppression
 Disease
• Congenital immunodeficiency
• Leukemia or lymphoma
• Generalized malignancy
 Cancer Therapy
• Alkylating agents
• Antimetabolites
• Radiation
Immunosuppressive Drugs
Immune mediators
Immune modulators
Iso-antibodies (therapeutic 
monoclonal antibodies)
–Antitumor necrosis factor agents
–B-lymphocyte depleting agent
Transplant rejection suppression
Checkpoint inhibition
Corticosteroids and Immunosuppression
 The amount or duration of corticosteroid therapy 
needed to increase adverse event risk is not well-
defined.
 Dose generally believed to be a concern:
 20 mg or more/day of prednisone for 2 weeks or 
longer
 2 mg/kg per day or more of prednisone for 2 
weeks or longer
Corticosteroids and Immunosuppression
 Does NOT apply to aerosols, topical, alternate-day, 
short courses (less than 2 weeks), physiologic 
replacement schedules
 Delay live vaccines for at least 1 month  after 
discontinuation of high-dose therapy
Vaccination of Immunosuppressed Persons
Safety: 
 Immunocompromised persons are at increased risk of 
adverse events following live vaccines.
 Live vaccines may be administered at least 3 months 
following termination of chemotherapy (at least 1 
month after high -dose steroid use of 2 weeks or more).
 LAIV, MMR, varicella, and  rotavirus vaccines may be 
administered to susceptible household and other close 
contacts.
Vaccination of Immunosuppressed Persons
 Safety and efficacy
 Anti-tumor necrosis factor inhibitors
• Wait 3 months after stopping medication before 
administering live vaccines
• Do not initiate medication until 1 months after the 
live vaccine 
 Other iso-antibodies (e.g., anti-B cell antibodies aka 
lymphocyte depleting agents, checkpoint inhibition)
• Some experts recommend  up to 6 months 
Persons with HIV Infection
Persons with HIV/AIDS are at increased 
risk for complications of measles, 
varicella, influenza, and pneumococcal 
disease.
Vaccine
Varicella
Zoster
MMR
MMRV
LAIV
Rotavirus
Yellow Fever
Asymptomatic
Yes
No
Yes
No
No
Consider
Consider
Symptomatic*
No
No
No
No
No
Consider
No
Yes=vaccinate   No=do not vaccinate
*See specific ACIP recommendations for details.
Live, Attenuated Vaccines for 
Persons with HIV/AIDS*
